ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of ONESOURCE SPECIALTY PHARMA LTD stock ₹249, price ₹1,613, that is 84.6% below the price, quality 26 out of 100. Rating: strongly overvalued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
ONESOURCE SPECIALTY PHARMA LTD
ONESOURCE · NSEFar too expensive (fair value 85% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.
How to read this chart
22‑month range ₹1,114 – ₹2,198 · fair‑value band ₹155.92 – ₹341.62 · the ₹1,613 price screens above the ₹248.77 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.
Every Wednesday you see whether ONESOURCE SPECIALTY PHARMA is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally.
Show moreShow less
The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics.
It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products.
The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India.
Stock analysis
ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE) currently trades at ₹1,613, while our model-based Fair Value estimate is ₹248.77, 85% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 92/100, which puts the data coverage at low.
Scenario range: ₹155.92 (bear) to ₹341.62 (bull), the price of ₹1,613 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
ONESOURCE SPECIALTY PHARMA LTD reported revenue of ₹14.2B in FY2026 versus ₹387M in FY2023, a compound +232.4%/yr. Reported net income was −₹738M in FY2026.
Key figures
Market cap ₹185B (≈ $2.0B) Small · P/S ratio 10.8 · EPS (TTM) ₹−0.1500 · Net margin −0.1% · Return on equity 0.0% · Return on assets (EBIT) −5.0% (4-year average) · Operating margin 17.3% · Revenue (TTM) ₹16.8B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 14% below its 52-week high and 45% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −85%, ONESOURCE screens richer than that median.
Fair Value models
All 2 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare ONESOURCE SPECIALTY PHARMA LTD with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- PEG ratio by industry
- Revenue growth by industry
- PEG screener for stocks with fair value
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs ONESOURCE |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs ONESOURCE |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs ONESOURCE |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs ONESOURCE |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs ONESOURCE |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs ONESOURCE |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs ONESOURCE |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs ONESOURCE |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs ONESOURCE |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs ONESOURCE |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE) overvalued or undervalued?
What is the fair value of ONESOURCE?
What is the quality score of ONESOURCE?
What is the price target for ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE)?
What is the ONESOURCE SPECIALTY PHARMA LTD stock forecast for 2026?
What is the revenue of ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE)?
What is the intrinsic value of ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE)?
Is ONESOURCE SPECIALTY PHARMA LTD stock overvalued or undervalued in 2026?
Is fair value the same as the market price of ONESOURCE?
How much is ONESOURCE SPECIALTY PHARMA LTD worth?
What do the bullish and bearish scenarios say about ONESOURCE?
How solid is the balance sheet of ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE)?
How far is ONESOURCE from its 52-week high?
Which stocks are comparable to ONESOURCE SPECIALTY PHARMA LTD?
Is ONESOURCE SPECIALTY PHARMA LTD stock attractive at the current price?
How is the fair value of ONESOURCE calculated?
Is it still worth investing in stocks now?
What is the share price of ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE)?
What should I pay attention to with ONESOURCE SPECIALTY PHARMA LTD right now?
Key figures of ONESOURCE SPECIALTY PHARMA LTD
How large is the market capitalisation of ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE)?
What is the P/S ratio of ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE)?
What are the earnings per share of ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE)?
What is the net margin of ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE)?
What is the return on equity of ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE)?
What is the EBIT return on assets of ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE)?
What is the operating margin of ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE)?
How fast is revenue growing at ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE)?
How fast are earnings growing at ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE)?
How much free cash flow does ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE) generate?
How much net debt does ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE) carry?
Watch ONESOURCE SPECIALTY PHARMA LTD in the live analysis
One click puts ONESOURCE SPECIALTY PHARMA LTD on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.